SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Boehringer Ingelheim Corporation Release: No Significant Difference in the Risk of Acute Coronary Syndrome (including Myocardial Infarction) Seen With Pradaxa®(dabigatran etexilate) Compared to Enoxaparin for VTE Prevention After Orthopaedic Surgery
Your Message